<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9414">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698329</url>
  </required_header>
  <id_info>
    <org_study_id>AIV007-E02</org_study_id>
    <nct_id>NCT05698329</nct_id>
  </id_info>
  <brief_title>Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME</brief_title>
  <official_title>A Phase 1 Study of the Safety, Pharmacokinetics, and Exploratory Efficacy of Periocular Administration of AIV007 in Subjects With Macular Edema Secondary to Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AiViva BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AiViva BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine safety, pharmacokinetics, and duration of effect of periocularly administered&#xD;
      AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or&#xD;
      diabetic macular edema (DME).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2023</start_date>
  <completion_date type="Anticipated">April 6, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Approximately 168 days</time_frame>
    <description>Incidence of adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in best-corrected visual acuity (BCVA)</measure>
    <time_frame>Approximately 168 days</time_frame>
    <description>Number of Early Treatment Diabetic Retinopathy Study (ETDRS) letters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central subfield thickness as measured by spectral domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>Approximately 168 days</time_frame>
    <description>SD-OCT read by a central reading center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to rescue medication</measure>
    <time_frame>Approximately 168 days</time_frame>
    <description>number of days to receive rescue medication</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>AIV007 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periocular injection, Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIV007 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periocular injection, Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIV007 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periocular injection, Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIV007 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Periocular injection, Dose 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIV007</intervention_name>
    <description>Periocular injection</description>
    <arm_group_label>AIV007 Dose 1</arm_group_label>
    <arm_group_label>AIV007 Dose 2</arm_group_label>
    <arm_group_label>AIV007 Dose 3</arm_group_label>
    <arm_group_label>AIV007 Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged 21-90 years (inclusive) at screening&#xD;
&#xD;
          2. BCVA in the study eye at screening and baseline/Day 1: ETDRS letter score ≤ 75 and ≥&#xD;
             24 (20/32 to 20/330 Snellen equivalent)&#xD;
&#xD;
          3. Subject must have received treatment within the 24 months before screening with&#xD;
             intravitreal (IVT) injections of an anti-VEGF agent with the last anti-VEGF injection&#xD;
             in the study eye being at least 6 weeks (42 days) before baseline/Day 1.&#xD;
&#xD;
          4. Subject has documentation of anti-VEGF responsiveness&#xD;
&#xD;
          5. Subject must provide written informed consent before any study-related procedures are&#xD;
             performed&#xD;
&#xD;
          6. Clear ocular media and adequate pupil dilation in both eyes to permit good-quality&#xD;
             photographic imaging&#xD;
&#xD;
        nAMD subject&#xD;
&#xD;
          1. The active CNV is confirmed by FA (evidence of leakage)&#xD;
&#xD;
          2. Residual intraretinal or subretinal fluid based on SD-OCT&#xD;
&#xD;
          3. CST ≥ 300 µm as assessed by SD-OCT&#xD;
&#xD;
          4. Total lesion size &lt; 10 disc areas (25.4 mm2)&#xD;
&#xD;
          5. Absence of geographic atrophy within 200 µm of the fovea&#xD;
&#xD;
          6. If subretinal hemorrhage is present, it must be &lt; 50% of the total CNV lesion and/or&#xD;
             not involve the fovea&#xD;
&#xD;
          7. If fibrosis is present, it must be &lt;50% of the total lesion area&#xD;
&#xD;
        DME subject&#xD;
&#xD;
          1. Diagnosis of diabetes mellitus (Type 1 or Type 2)&#xD;
&#xD;
          2. Subject has clinically significant DME with central involvement (CST≥300 μm by OCT)&#xD;
&#xD;
          3. The decrease in vision in the study eye was determined by the investigator to be&#xD;
             primarily the result of DME&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment for nAMD or DME in the study eye other than standard-of-care&#xD;
             anti-VEGF IVT injection, e.g., cell therapy, brachytherapy, gene therapy&#xD;
&#xD;
          2. Uncontrolled IOP, defined as an IOP &gt; 25 mmHg&#xD;
&#xD;
          3. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) &gt;10% at&#xD;
             screening visit&#xD;
&#xD;
          4. The spherical equivalent for refractive error in the study eye of worse than 8.0&#xD;
             diopters of myopia (before cataract or refractive surgery) per the current&#xD;
             prescription&#xD;
&#xD;
          5. Any history of active bacterial, viral, fungal, or parasitic ocular or periocular&#xD;
             infection, or intraocular inflammation in either eye within the 30 days before the&#xD;
             screening Visit&#xD;
&#xD;
          6. History of vitreous hemorrhage within 3 months before screening in the study eye&#xD;
&#xD;
          7. Uncontrolled systemic disease or any other condition or therapy that would make the&#xD;
             participant unsuitable for the study&#xD;
&#xD;
          8. Participation in any investigational study within 60 days before the screening visit,&#xD;
             or planned use of an investigational product or device during the study; any exposure&#xD;
             to a prior investigational drug product must be fully washed out (at least 5&#xD;
             half-lives)&#xD;
&#xD;
          9. History of allergy or hypersensitivity to constituents of the study treatment&#xD;
             formulation, topical iodine, ocular antimicrobial solutions, or clinically relevant&#xD;
             hypersensitivity to fluorescein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darlene Deecher, PhD</last_name>
    <phone>9496621949</phone>
    <phone_ext>4</phone_ext>
    <email>office@aiviva.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Wang, PhD</last_name>
    <phone>9496621949</phone>
    <phone_ext>4</phone_ext>
    <email>office@aiviva.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Consultants of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

